Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

Chunxin Lv1*, Xiuju Liu2*, Qiwen Zheng3, Hanxiao Chen4, Xue Yang4, Jia Zhong4, Yuyan Wang4, Jianchun Duan5, Zhijie Wang6, Hua Bai5, Meina Wu4, Jun Zhao4, Jie Wang5, Ziping Wang4, Minglei Zhuo4

1 Geriatric Department, Minhang Hospital, Fudan University, Shanghai, China
2 Department of Medical Oncology, Shandong Cancer Hospital and Institute, Jinan, China
3 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
4 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital and Institute, Beijing, China
5 Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Keywords
Second-line chemotherapy; small cell lung cancer; topoisomerase-1; topotecan.

Correspondence
Minglei Zhuo and Tongtong An, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Medical Oncology-I, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian District, Beijing 100142, China.
Tel: +86 10 8819 6456
Fax: +86 10 8819 6562
Email: minglei1978@163.com; antt508@sina.com

*These authors contributed equally to this work.

Received: 27 May 2018;
Accepted: 23 June 2018.

doi: 10.1111/1759-7714.12819

Abstract

Background: We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second-line topotecan chemotherapy.

Methods: We retrospectively evaluated the records of SCLC patients treated in our department from January 2007 to December 2016 who received second-line topotecan chemotherapy. Patients with archived tumor samples were enrolled. TOPO1 expression levels were evaluated by immunohistochemistry, and the relationships between TOPO1 expression, clinical factors, chemotherapy efficacy, and survival were analyzed.

Results: Of the 78 patients enrolled, 67 showed TOPO1 expression (85.9%). Patients were divided into strong (n = 43) or weak (n = 35) expression groups based on staining intensity. Disease control rates for topotecan were 39.5% and 14.3% in the strong and weak groups, respectively (P = 0.014). Second-line median progression-free survival was 2.2 and 2.0 months (P = 0.057), and median overall survival was 8.1 and 6.0 months (P = 0.199) in the strong and weak positive groups, respectively. Patients were also divided into sensitive (n = 47) and refractory (n = 31) disease groups according to the duration from the onset of first-line therapy to relapse. Median second-line progression-free survival was 2.2 and 1.8 months in the sensitive and refractory relapse groups, respectively (P = 0.005).

Conclusions: TOPO1 expression was prevalent in SCLC patients. Strong expression was associated with an elevated disease control rate after second-line topotecan chemotherapy. Patients with sensitive disease that relapsed after first-line chemotherapy had better survival than refractory patients who received second-line topotecan chemotherapy.

Introduction

Lung cancer is a severe worldwide health problem, particularly in China. Small cell lung cancer (SCLC) is the most aggressive subtype and accounts for approximately 14% of all lung cancers. In the United States (US), approximately 31 000 patients are diagnosed with SCLC annually. Despite numerous clinical trials since the 1970s, including at least
40 phase III trials, systemic treatment for patients with SCLC has not changed significantly over the past few decades. Consequently, the five-year survival rate for this type of lung cancer remains low at < 7%, with the majority of patients surviving less than a year after diagnosis.1

Currently, the main treatments for SCLC include chemotherapy and radiotherapy, with a response rate of approximately 70% to first-line chemotherapy.5,6 However, the efficacy of second-line therapy is low because of drug resistance, resulting in poor prognosis.6,7 At present, topotecan is the only agent approved by the US Food and Drug Administration (FDA) for recurrent or progressive SCLC.10,11 Topotecan works by inhibiting topoisomerase I (TOPO1), a nuclear enzyme that relieves torsional strain during DNA replication by creating single strand breaks.12,13 Topotecan binding to the DNA cleavage complex prevents TOPO1 from re-ligating the nicked DNA strand after relieving the strain. This intercalation therefore traps TOPO1, leading to DNA damage.14 The unbroken DNA strand then breaks, resulting in a double-stranded break that mammalian cells are unable to efficiently repair.15 This action prevents DNA replication and ultimately leads to cancer cell death.

However, response rates to topotecan in cases of relapsed SCLC are reported at approximately 20%.9,16,17 Effective predictive markers are needed to improve the selection of sensitive patients.18 In vitro studies have shown that high TOPO1 expression levels are associated with improved sensitivity to TOPO1 inhibitors in cancer cells.19 However, it is not clear whether TOPO1 could serve as a predictive marker for topotecan efficacy in patients with SCLC.20,21 In this study, therefore, we examine TOPO1 expression levels and explore the potential predictive markers for the response to topotecan chemotherapy in SCLC patients.

**Methods**

**Patients**

The study was approved by the Ethics Committee of the Peking University Cancer Hospital in Beijing, China. Consent was obtained from all patients diagnosed with SCLC who received topotecan chemotherapy in our department between January 2007 and December 2016, identified through the hospital database. Inclusion criteria were: pathological diagnosis of SCLC; topotecan administered as second-line chemotherapy; Eastern Cooperative Oncology Group performance status (ECOG-PS) 0–2; and the availability of archived tissue samples for immunohistochemical analysis. Disease recurrence was assessed by computed tomography (CT) scanning, magnetic resonance imaging (MRI), bone scanning, and various tumor markers. All staging procedures were carried out using the 7th Union for International Cancer Control tumor node metastasis (TNM) classification. We collected details on the dates from initiation of chemotherapy to disease progression, gender, age, smoking status, disease stage, chemotherapy response, survival and pathologic subtype, and ECOG PS.22 The therapy response was assessed according to Revised Evaluation Criteria in Solid Tumors (RECIST) version 1.1.21 Second-line progression-free survival (PFS) was measured from the date of toptotecan administration to the date of documented disease progression. Second-line overall survival (OS) was calculated as the date of toptotecan administration to the date of death. First-line OS was measured from the date first-line chemotherapy was commenced to the date of death.

**Immunohistochemical analysis**

Samples were obtained at the time of diagnosis in 69 (88.5%) patients and 9 (11.5%) provided re-biopsy samples at the time of disease progression before commencing toptotecan chemotherapy. TOPO1 expression was examined by immunohistochemistry (IHC) using an anti-TOPO1 antibody (ab85038, Abcam, Cambridge, UK).24,25 Two central pathologists who were not involved in patient management decisions and were blinded to study treatment verified the IHC results. Five fields of view were analyzed in each slide, and a semi-quantitative H-score ranging from 0 to 300 was calculated by multiplying the percentage of positively stained cells by an intensity score (0, absent; 1, weak; 2, moderate; 3, strong). Patients with an H-score of 200–300 were classified into the “strong expression” group, and the remainder was classified into the “weak expression” group, including those with negative expression.

**Statistical analysis**

Frequencies and proportions were reported for categorical variables, and the mean and median for continuous variables. Univariate analysis was performed using chi-square or Fisher’s exact tests for categorical variables, and independent sample t or Wilcoxon rank sum tests for normal and non-normal continuous variables, respectively.

We used the Kaplan–Meier method to describe OS and PFS. The log-rank test was utilized to test for differences in OS and PFS between groups. A log-log survival plot of the categorical variables was used to determine whether the proportional hazards assumption was appropriate, and all variables were fit to the proportional hazards assumption. The impact of TOPO1 expression on overall and cancer-specific survival was assessed by Cox proportional hazard models with and without risk-adjustment for age, gender, smoking status, tumor stage, response to first-line...
chemotherapy, response to second-line chemotherapy, and type of relapse.

Statistical analysis was performed with R software version 3.3.3 (R Foundation for Statistical computing, Vienna, Austria). The reported significance levels were all two-sided, with statistical significance set at 0.05.

Results

Patient characteristics

A total of 78 patients were included in the present study. The median age was 61 years (range: 39–80), and the proportion of male and female patients was 82.0% and 18.0%, respectively. The demographic and clinical characteristics of the primary cohort are shown in Table 1. There were 24 limited and 54 extensive stage cases. First-line chemotherapy regimens comprised etoposide plus cisplatin (EP) or etoposide plus carboplatin (EC), and had a response rate (RR) of 87.2% and a median PFS of 5.6 months. Second-line chemotherapy consisted of single-agent topotecan, and had a disease control rate (DCR) of 28.2% and a PFS of 2.1 months. The OS for second-line chemotherapy was 8.5 months.

Adverse effects included gastrointestinal (71.5%), hematological (62.3%), and liver and kidney (23.5%) toxicities. Most adverse effects were tolerable, and no patients withdrew from treatment or died as a result of chemotherapy toxicity.

Topoisomerase 1 (TOPO1) expression analysis by immunohistochemistry

TOPO1 staining was positive in 67 patients (85.9%) and negative in 11 (14.1%) (Fig 1). All patients were divided into two groups according to the extent of TOPO1 expression: 43 (55.1%) were categorized into the strong, and 35 (44.9%) into the weak expression group. There were no significant differences in age, gender, stage, and first-line RRs between the two groups (Table 1). No significant difference was detected in the TOPO1 strong expression ratio between those with limited and extensive stages of cancer (50% vs. 57.4%, respectively; \( P = 0.544 \)) (Table 1).

Topotecan efficacy in patients with different TOPO1 expression levels

Topotecan efficacy was compared between the strong and weak expression groups. In the strong expression group there were 3 cases of partial remission (PR), 14 stable disease (SD), and 26 progressive disease (PD), while in the weak group there were no cases of PR, 5 SD, and 30 PD. There was a significant difference in the DCR between the strong and weak expression groups (39.5% vs. 14.3%, respectively; \( P = 0.014 \)) (Table 1), but no significant difference was detected in survival between the groups. Median second-line PFS was 2.2 (range 2.0–not applicable [NA]) and 2.0 (range 1.9–2.3) months in the strong and weak expression groups, respectively (\( P = 0.057 \)) (Fig 2a). Median second-line OS was 8.1 (range 6.3–11.2) and 6.0 (range 5.7–8.8) months in the strong and weak expression groups, respectively (\( P = 0.199 \)) (Fig 2b). Median first-line OS was 15.3 (range: 12.7–17.4) and 12.5 (range 10.1–14.5) months in the strong and weak expression groups, respectively (\( P = 0.134 \)) (Fig 2c).

The results of univariate analysis are shown in Table 2. Multivariate analysis demonstrated that TOPO1 expression, clinical stage, and type of relapse were independent risk factors for poor second-line PFS in response to topotecan therapy (Table 3). However, TOPO1 expression failed to show any predictive value for OS or survival after topotecan chemotherapy. In addition, smoking status, clinical stage, and response to topotecan therapy were independent risk factors for poor survival after topotecan therapy. Additional risk factors for poor OS were also type of relapse and response to first-line therapy.
Patients were then divided into two groups based on TOPO1 expression: 67 patients had positive and 11 had negative expression. There were no significant differences in age, gender, clinical stage, or response to first-line chemotherapy between these groups (Table S1). The DCR in response to topotecan therapy was much higher in the TOPO1 positive compared to the negative group (32.8% vs. 0%, respectively; \( P = 0.028 \)) (Table S1). The median PFS after second-line chemotherapy was 2.2 (interquartile range [IQR] 2.0–2.6) and 1.9 (IQR 1.7–NA) months in the positive and negative groups, respectively (\( P = 0.022 \); Fig S1), while the median OS after second-line chemotherapy was 7.8 (6.1–8.9) and 5.9 (5.1–NA) months, respectively (\( P = 0.453 \)) (Fig S2).

**Topotecan efficacy is associated with relapse time after initial therapy**

It has been shown that the response to second-line therapy is highly dependent on the time interval from the onset of first-line therapy to relapse. If the interval is < 3 months (refractory disease), the response to most agents or regimens is < 10%, and if > 3 months have elapsed (sensitive disease), the expected response rates are approximately 25%.

Based on these findings, patients in this study were divided into two groups: those with refractory (\( n = 31 \)) and sensitive (\( n = 47 \)) disease. In the sensitive disease group, responses to second-line chemotherapy included
3 PR, 15 SD, and 29 PD, while in the refractory disease group there were no cases of PR, 4 SD, and 27 PD. Hence, there was a significant difference in the DCR between the sensitive and refractory groups (38.3% vs. 12.9%, respectively; \( P = 0.038 \)).

The median PFS after second-line chemotherapy was 2.2 (IQR 2.0–NA) and 1.8 (IQR 1.5–2.3) months \((P = 0.005)\) in the sensitive and refractory groups, respectively (Fig 2d).

The median OS after second-line chemotherapy was 8.2 (IQR 7.1–9.2) and 5.1 (IQR 4.5–11.3) months in the sensitive and refractory groups, respectively \((P = 0.038)\) (Fig 2e). The median OS after first-line chemotherapy was 14.8 (IQR 13.8–16.8) and 9.1 (IQR 8.4–15.8) months in the sensitive and refractory groups, respectively \((P = 0.131)\) (Fig 2f).

**Discussion**

To the best of our knowledge, this is the first study to show that TOPO1 expression levels are associated with DCR.
after topotecan therapy in Chinese patients with SCLC. The DCR was much higher in the strong than in the weak positive expression group. We also confirmed that in relapse cases, patients with sensitive disease had better survival after topotecan therapy than those with refractory disease. The proportion of patients with positive TOPO1 expression (85.9%), the first-line chemotherapy RR (87.2%), and DCR after topotecan therapy (28.2%) in our study were similar to data reported in previous studies.27–29

Previous in vitro studies have revealed that higher TOPO1 inhibitor efficacy is associated with increased TOPO1 expression levels.19,20,30 However, results from clinical trials on solid tumors are controversial. For instance, in 2014, Nygård et al. reported that there was no significant correlation between TOPO1 expression levels and irinotecan (a TOPO1 inhibitor) efficacy in colorectal cancer.31 Conversely, Guo et al. studied 50 cases of SCLC and reported that TOPO1 expression levels were higher in late stage than in early stage disease, and that high TOPO1 expression is a rationale to indicate TOPO1 inhibitor treatment of malignancies.27 Brunner et al. reported that low TOPO1 levels identified a group of patients with stage III colon cancer that would not benefit from irinotecan adjuvant treatment.32 Unlike prior studies, we used the semi-quantitative H-score method to evaluate TOPO1 protein levels, and found that the DCR was significantly higher in the strong than in the weak expression group. Similarly, the DCR in patients with positive TOPO1 expression of any intensity was better than that in those with no expression. Our results indicated that the TOPO1 expression level evaluated using the H-score method could serve as a potential predictor for topotecan efficacy in SCLC.

We explored the prognostic value of TOPO1 expression. No significant difference in survival was observed between the groups with strong and weak TOPO1 expression in Kaplan–Meier survival analysis, nor was a significant relationship observed between TOPO1 expression level and survival in univariate regression analysis. However, in

---

**Table 2** Univariate analysis of the primary cohort (n = 78)

| Characteristic                      | PFS after topotecan therapy | Survival after topotecan therapy | OS                  |
|-------------------------------------|----------------------------|----------------------------------|---------------------|
|                                     | HR (95% CI)                | P                                | HR (95% CI)         | P                                  |
| Smoking status: Smoker              | 1.119 (0.610–2.050)       | 0.717                            | 1.652 (0.994–2.901) | 0.053                             |
| Clinical stage: Disseminated        | 1.884 (1.025–3.464)       | 0.041                            | 2.347 (1.366–4.033) | 0.008                             |
| TOPO1 expression: Strong positive   | 0.598 (0.352–1.015)       | 0.057                            | 0.739 (0.467–1.711) | 0.134                             |
| Response to first-line chemotherapy: Stable disease | 0.710 (0.304–1.658)       | 0.429                            | 1.221 (0.622–2.398) | 0.362                             |
| Type of relapse: Sensitive disease  | 0.470 (0.277–0.796)       | 0.005                            | 0.871 (0.542–1.399) | 0.131                             |
| Response to second-line chemotherapy: Disease progression | —                        | —                                | 2.830 <0.001        | 2.934 (1.699–5.068) < 0.001       |

CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TOPO1, topoisomerase 1.

---

**Table 3** Multivariate analysis of the primary cohort (n = 78)

| Characteristic                      | PFS after topotecan therapy | Survival after topotecan therapy | OS                  |
|-------------------------------------|----------------------------|----------------------------------|---------------------|
|                                     | HR (95% CI)                | P                                | HR (95% CI)         | P                                  |
| Smoking status: Smoker              | —                          | —                                | 1.915 (1.076–3.406) | 0.027                             |
| Clinical stage: Disseminated        | 2.856 (1.487–5.487)        | 0.001                            | 2.421 (1.352–4.337) | 0.006                             |
| TOPO1 expression: Strong positive   | 0.431 (0.247–0.753)        | 0.003                            | 0.937 (0.572–1.537) | 0.336                             |
| Response to first-line chemotherapy: Stable disease | —                        | —                                | 1.887 (0.934–3.814) | 0.301                             |
| Type of relapse: Sensitive disease  | 0.313 (0.176–0.557)        | < 0.001                          | —                   | 0.498                             |
| Response to second-line chemotherapy: Disease progression | —                        | —                                | 2.732 <0.001        | 2.323 (1.628–5.068) < 0.001       |

CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TOPO1, topoisomerase 1.
multivariate regression analysis, TOPO1 expression was significantly associated with second-line PFS ($P = 0.003$). This discrepancy may be caused by the sample size and confounding factors such as age, staging, and topotecan response. We conclude that OS was affected by subsequent chemotherapy and local radiotherapy. In the strong TOPO1 expression group, 14 (32.6%) patients received third-line chemotherapy, while in the weak expression group, 13 (37.1%) patients received subsequent chemotherapy. Thirty-one (72.1%) and 28 (80%) patients received local radiotherapy (thorax, brain, or bone) in the strong and weak TOPO1 expression groups, respectively. Our results suggest the possibility that TOPO1 expression level might be a predictor for PFS after topotecan therapy.

Our data demonstrate that among relapsed patients, those with sensitive disease could benefit more than those with refractory disease after second-line chemotherapy; this result was consistent with those of a previous study.33 Topotecan is effective for patients with sensitive disease; however, second-line chemotherapy efficacy was low for those with refractory disease. Therefore, patients with refractory disease require therapy with alternative, more efficient agents. In recent years, new agents such as amrubicin and immunotherapy with antibodies against PD-1 and CTLA-4 represent promising alternatives for patients with SCLC.11,12,34

Guo et al. reported that clinical staging of SCLC was associated with TOPO1 expression levels; patients with advanced stage cancer exhibit higher TOPO1 expression than early stage patients.27 However, we did not find any significant differences in TOPO1 levels between limited and advanced stage patients (50% and 57.4% of patients with strong positive TOPO1 expression, respectively; $P = 0.544$). Possible reasons for this could be clinicopathological differences in enrolled patients, examination techniques, or the antibodies used. Further investigation is therefore warranted.

There were some limitations to this retrospective study. The limited sample size made it difficult to detect a significant difference in PFS between the groups with strong and weak TOPO1 expression. The imbalance in patient numbers between the TOPO1 positive and negative groups (67 vs. 11 cases) could also influence the reliability of these conclusions. In future, large scale prospective studies combined with multigene analysis could help to identify more valuable prognostic and predictive markers in SCLC.

In conclusion, the results of our study show that TOPO1 expression is highly prevalent in SCLC. In the second-line topotecan chemotherapy group, patients with strong TOPO1 expression had better DCR than those with weak expression, and sensitive relapse patients had longer PFS than those with refractory disease. Our findings indicate that the TOPO1 expression level could serve as a potential predictive marker for topotecan efficacy in SCLC.

Acknowledgments

This study was funded by the Beijing Natural Science Foundation (Commission No. 7162038) and the Beijing Municipal Administration of Hospitals’ Youth Programme (Commission No. QML20161101).

Disclosure

No authors report any conflict of interest.

References

1. Zheng R, Zeng H, Zhang S, Chen W. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer 2017; 36: 66.
2. Chen W, Zheng R, Zhang S et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res 2014; 26: 48–58.
3. Parikh M, Riess J, Lara PNJ. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol 2016; 28: 97–103.
4. Byers LA, Rudin CM. Small cell lung cancer: Where do we go from here? Cancer 2015; 121: 664–72.
5. Berghmans T, Scherperel A, Meert AP et al. A phase III randomized study comparing a chemotherapy with cisplatin and etoposide to a etoposide regimen without cisplatin for patients with extensive small-cell lung cancer. Front Oncol 2017; 7: 217.
6. Kalemkerian GP, Akerley W, Bogner P et al. Small cell lung cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2013; 11: 78–98.
7. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res 2016; 5: 26–38.
8. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539–44.
9. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007; 57 (Suppl 2): S30–4.
10. Sun Y, Cheng Y, Hao X et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer 2016; 16: 265.
11. Pietanza MC, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: Will recent progress lead to improved outcomes? Clin Cancer Res 2015; 21: 2244–55.
12. Zauderer MG, Drilon A, Kadota K et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed
small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer 2014; 86: 237–40.
13 Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerase and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010; 17: 421–33.
14 Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006; 6: 789–802.
15 Staker BL, Hjerrild K, Behnke CA, Burgin ABJ, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002; 99: 15387–92.
16 Horita N, Yamamoto M, Sato T et al. Topotecan for relapsed small-cell lung cancer: Systematic review and meta-analysis of 1347 patients. Sci Rep 2015; 5: 15437.
17 Pillai RN, Owonikoko TK. Small cell lung cancer: Therapies and targets. Semin Oncol 2014; 41: 133–42.
18 Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer 2014; 120: 790–8.
19 Kotoh S, Naito S, Yokomizo A et al. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 1994; 54: 3248–52.
20 Fukuoka K, Adachi J, Nishio K et al. p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 1997; 88: 1009–16.
21 Riemsma R, Simons JP, Bashir Z, Gooch CL, Kleijnen J. Systematic review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010; 10: 436.
22 Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–56.
23 Eisenhauer EA, Therasse P, Bogaerts J et al. New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47.
24 Guzman-Ayala M, Sachs M, Koh FM et al. Chd1 is essential for the high transcriptional output and rapid growth of the mouse epiblast. Development 2015; 142: 118–27.
25 Boichuk S, Lee DJ, Mehalek KR et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res 2014; 74: 1200–13.
26 National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Small Cell Lung Cancer. [Cited 12 May 2018.] Available from URL: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
27 Guo QS, Liu YY, Yu JM, Wang JL, Zhong WX, Liu XJ. Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2007; 29: 124–6 In Chinese.
28 Jotte R, Conkling P, Reynolds C et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011; 29: 287–93.
29 von Pawel J, Jotte R, Spigel DR et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9.
30 Liao Z, Robey RW, Guirouilh-Barbat J et al. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and dolomotecan. Mol Pharmacol 2008; 73: 490–7.
31 Nygård SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brünnner N, KL S. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scand J Gastroenterol 2014; 49: 84–91.
32 Brunnner N, Nygaard SB, Budinska E, Stenvang J. ABCG2 and TOP1 mRNA expression as predictive biomarkers for adjuvant FOLFIIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial. J Clin Oncol 2017; 35: (4 Suppl 1): Abstract 591.
33 Owonikoko TK, Behera M, Chen Z et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol 2012; 7: 866–72.
34 Hellmann MD, Ott PA, Zugazagoitia J et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 2017; 35: (15 Suppl): Abstract 8503.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

Table S1 Clinical characteristics of the negative and positive topoisomerase 1 (TOPO1) expression groups

Figure S1 CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.

Figure S2 Overall survival after second-line topotecan chemotherapy in the topoisomerase-1 positive group compared to the negative group.